T he use of peripherally inserted central venous catheters (PICCs) has increased significantly in recent years, 1, 2 in part due to perceived advantages over other forms of venous access, particularly among patients with difficult-to-obtain intravenous access. It is generally accepted that PICCs are safe and effective while having the benefits of ease of placement, a lower rate of procedure-related complications, and the potential for lower costs in comparison to other forms of venous access. 3, 4 Most importantly, PICCs are viewed as highly convenient for both patients and physicians because they are often inserted by nurse-led teams, can be used for phlebotomy, can substitute for nontunneled central lines that have greater insertion-associated risk, and can remain in place following discharge, allowing for home rather than hospital administration of medications, including antibiotics (Table 1) . Despite what is seen as a favorable safety profile, significant complications related to PICC placement are now increasingly recognized. 1 Patients with chronic kidney disease (CKD), including those receiving dialysis, may disproportionately receive PICCs. 5, 6 Patients with CKD, including those with additional comorbid conditions such as diabetes, heart failure, and vascular disease, have high rates of hospitalization and require frequent administration of intravenous therapies, such as antibiotics to treat infections. Given often extensive histories of medical encounters, they may also have limited veins for peripheral intravenous access. Accordingly, PICCs are more likely to be placed in patients with acute kidney injury and CKD. 7 With prior research showing that PICCS are associated with a high rate of upper-extremity venous thrombosis and residual central venous stenosis, 5 this may have future implications for these patients, including impacts on future hemodialysis vascular access creation and longevity. 8 
WHAT DOES THIS IMPORTANT STUDY SHOW?
A recent study by Greene et al 9 published in the American Journal of Medicine assessed the association between PICC placement and venous thromboembolism among more than 76,000 patients admitted to 48 Michigan hospitals between January 2011 and March 2014. Eligible patients included only those admitted to a medicine service for acute care for 2 days or longer, excluding patients admitted directly to an intensive care unit and those hospitalized for surgery. Additional exclusions were known venous thromboembolism within 6 months and admission for presumed thromboembolism. Using medical record review and telephone follow-up 90 days postdischarge, investigators ascertained outcomes of interest, specifically symptomatic image-confirmed deep venous thrombosis of the upper or lower extremity, as well as pulmonary embolism. Medical record review was completed in 100% of participants, whereas telephone contact occurred in 58%.
Among 76,242 eligible participants, 3,790 (5%) had a PICC either at hospital admission (n 5 898) or during the hospital stay (n 5 2,892). Those with a PICC had more comorbid conditions, including more frequent hospitalizations during the prior year, with a higher proportion with cancer, recent surgery, immobility, and sepsis. Data for kidney measures are not reported. In analyses adjusting for potential venous thrombosis-related risk factors such as older age, immobility, cancer, and recent surgery, as well as other factors, PICC use was independently associated with a 3 times greater hazard of all-cause thromboembolism (hazard ratio [HR], 3.16 [95% confidence interval (CI), 2.59-3.85]). This finding was driven by upper-extremity deep venous thrombosis, with a 10-fold greater hazard for those with PICCs (HR, 10.49; 95% CI, 9.79-14.11). PICC use was also associated with a 1.5-fold greater hazard of lower-extremity deep venous thrombosis (HR, 1.48; 95% CI, 1.02-2.15), but was not associated with pulmonary embolism. No change was seen in study results when the study authors included the use of deep venous thrombosis prophylaxis.
Although the association between PICC use and upper-extremity thrombosis is intuitive, the significant albeit lower magnitude association with lower-extremity thrombosis is less clear. The authors posit 3 factors: (1) ascertainment bias, (2) PICCs may trigger a systemic prothrombic milieu, and (3) there may be additional unmeasured confounding factors associated with increased thrombosis risk regardless of the PICC. Supporting the third possible factor, those with PICCs in place are clearly sicker patients with higher risk for thromboembolism. Potentially, the authors could have attempted to better account for unmeasured factors using alternative statistical methods, such as inverse probability treatment weighting or propensity score-based matching. 10 Despite this shortcoming, it is remarkable how high the risk for upper-extremity clots is with PICCs, even if this "baseline" thrombosis risk represented by lower-extremity thrombosis is considered.
One strength of the study is the use of a detailed database of hospital admissions that includes one of the largest cohorts of patients with PICCs. The authors have also separated thromboembolic events into 3 different distinct outcomes of upper deep venous thrombosis, lower deep venous thrombosis, and pulmonary embolism, allowing a more accurate rate of upper-extremity deep venous thrombosis to be determined. A major weakness is the use of retrospective design, which may bias toward more deep venous thrombosis events in the PICC group 
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HOW DOES THIS STUDY COMPARE WITH PRIOR STUDIES?
Multiple previous studies have demonstrated higher risk for deep venous thrombosis in patients with PICCs. A meta-analysis by Chopra et al 11 published in 2013 attempted to include the existing literature published on PICCs and thromboembolic events. The majority of published articles included in this analysis had small numbers of patients, did not discriminate between upper and lower deep venous thrombosis, and did not adjust for thromboembolic risk factors. Overall, PICCs were found to be strongly associated with deep venous thrombosis, but not with pulmonary embolism, similar to the finding by Greene et al. Subgroup analyses showed that prospective studies and those using asymptomatic surveillance had higher rates of thromboembolism, suggesting that this retrospective study may have underestimated the true incidence of thromboembolic events.
WHAT SHOULD CLINICIANS AND RESEARCHERS DO?
This study raises concerns about the safety of PICCs, almost certainly underestimating total upperextremity thrombosis due to potentially asymptomatic cases, as well as not identifying vein trauma that may lead to stenosis and predispose to future vein failure. Supporting this pathophysiology, a case-control study of hemodialysis patients by El Ters et al 8 showed a strong independent association between PICC use and lack of a functioning arteriovenous fistula. Similarly, a retrospective study of hemodialysis patients also showed that the presence of transvenous cardiac device wires was associated with more radiologic central vein stenosis and a higher likelihood of being catheter dependent.
12
Reflecting potential concerns about PICC overuse, a recently published guide in the Annals of Internal Medicine addressed scenarios in which PICC use could be considered acceptable, 13 positing that PICC use was acceptable only when the duration of use was longer than 6 days unless nonperipherally compatible infusions were needed (eg, sclerosing antibiotics or chemotherapy). Among patients with CKD stage 3b or higher (estimated glomerular filtration rate , 45 mL/min/1.73 m 2 ), PICC use was almost always considered unacceptable, largely due to the high likelihood of peripheral and central venous complications (including thrombosis) interrupting future hemodialysis access. This guide urged nephrology input prior to PICC placement in these individuals to facilitate assessment of risk versus benefit and argued strongly for using PICCs only in cases of clinical necessity, pushing back against the now common use of PICCs for patient and provider convenience.
A comprehensive guide outlining PICC indications is a step in the right direction, but this is unlikely to be sufficient to change clinical practice on its own. Nephrologists need to remain vigilant in preventing PICC placement in patients with CKD. Protocols that require nephrology consultation for any PICC request in patients with reduced kidney function (including acute kidney injury) are a good starting point and may be facilitated with electronic alerts or stops triggered in electronic order entry systems. Such policies have the benefit of involving a nephrologist in decision making before potentially harmful decisions are made. Importantly, non-nephrologist clinicians need to become more familiar with vein protection strategies aimed at preserving future hemodialysis access. All providers should be aware that any foreign object that sits within a blood vessel, whether a catheter or device wire/lead, has the potential to cause vascular damage, leading to diminished prospects for future hemodialysis access. Finally, patients with CKD need to be informed about the potential risks of PICCs so they can make a fully informed decision about their health care. 
